The effects of blocking angiotensin receptors on early stages of diabetic nephropathy

International Journal of Preventive Medicine

Volumn 3, Issue 7, 2012, Pages 477-482

  Gheissari, Alaleh ^a   Javanmard, Shaghayegh Haghjooy ^b   Shirzadi, Roohollah ^c   Amini, Masood ^d   Khalili, Nooshin ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiotensin receptor blocker; Diabetic nephropathy; Endothelial dysfunction; Valsartan

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; ONSET AGE; PATIENT ASSESSMENT; RECEPTOR BLOCKING; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; UPREGULATION; URINALYSIS; URINE CULTURE;

EID: 84864070788     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 2002;4:224-38.
2. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci(Lond) 2007;112:375-84.
3. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, WannerC, Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003;18:1716-25.
4. de Haro Miralles J, Martinez-Aguilar E, Florez A, Varela C, Bleda S, Acin F. Nitric oxide: Link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs. Interact Cardiovasc Thorac Surg 2009;9:107-12.
5. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993;87(Suppl. V):V67-76.
6. Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM. Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in endothelium of the genetic diabetic BB rat. Diabetologia 1997;40:910-5.
7. Romuk E, Jagosz J, Skrzep-Poloczek B, WojciechowskaC, Strojek K, Se{ogonek}dek L, et al. Evaluation of VCAM-1 and PAI-1 concentration in diabetes mellitus patients. Experimental and Clinical Diabetology; 2008;8:85-8.
8. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010;6:319-30.
9. Salardi S, Balsamo C, Zucchini S, Maltoni G, Scipione M, Rollo A, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type1 diabetes treated or not with enalapril: The influence of HDL cholesterol. Diabetes Care 2011;34:424-9.
10. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. N Engl J Med 2011;364:907-17.
11. Levey SA, Eckardt KU, Tsukamuto Y, Levin A, CoreshJ, Rossert J, et al. Definition and classification of chronic kidney disease: Aposition statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
12. Czekalski S. How to diagnose and how to interpret microalbuminuria in the diabetic patient. Nephrol Dial Transplant 1996;11:1509-11.
13. Dirsch MV, Stuppner H, Vollmar MA. The Griess Assay: Suitable for a bio-guided fractionation of anti-inflammatory plant extracts? Planta Med 1998;64:423-6.
14. Perkins BA, Aiello LP, Krolewski AS. Diabetes complications and the renin-angiotensin system. NEngl J Med 2009;361:83-5.
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEngl J Med 1993;329:1456-62.
16. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Ann Intern Med 2009;151:11-20.
17. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type1 diabetes. NEngl J Med 2009;361:40-51.
18. Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy: Comparing telmisartan's and losartan's effects on proteinuria. Kidney Int 2008;74:364-9.
19. Meigs BJ, Hu BF, Rifai N, Manson EJ. Biomarkers of endothelial dysfunction and risk of type2 diabetes mellitus. JAMA 2004;291:1978-86.
20. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: Cause of the insulin resistance syndrome. Diabetes 1997;46:S9-13.
21. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, et al. Blood flow and muscle metabolism: Afocus on insulin action. Am J Physiol Endocrinol Metab 2003;284:E241-58.
22. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008;23:1621-7.
23. StehouwerCD, NautaJJ, ZeldenrustGC, HackengWH, DonkerAJ, den OttolanderGJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319-23.
24. Aizawa JK, Shoemaker K, Overend TJ, Petrella RJ. Metabolic syndrome, endothelial function and lifestyle modification. DiabVasc Dis Res 2009;6:181-9.
25. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
26. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest 1995;96:60-8.
27. Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links. Am J Hum Genet 1999;64:673-7.
28. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:H321-6.
29. Tesfamariam B, Brown ML, Cohen RA. 15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta. JCardiovasc Pharmacol 1995;25:748-55.
30. Lin YK, Ito A, Asagami T, Tsao SP, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-92.
31. Calver A, Collier J, Valiance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. JClin Invest 1992;90:2548-54.
32. Holmlund A, Hulthe J, Millgard J, Sarabi M, Kahan T, Lind L. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis 2002;165:271-6.
33. Witte DR, Broekmans WM, Kardinaal AF, Klöpping-Ketelaars IA, van Poppel G, Bots ML, et al. Soluble intercellular adhesion molecule1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 2003;170:147-53.
34. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD (P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000;87:1195-201.
35. Hernandez-Presa M, Bustos C, Ortego M, Tuñon J, RenedoG, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
36. Jilma B, Li-Saw-Hee FL, Wagner OF, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein. Clin Sci (Lond) 2002;103:131-6.
37. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotens in receptor blockade decreases markers of vascular inflammation. JCardiovasc Pharmacol 2004;44:335-9.
38. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999;12:217-22.
39. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type2 diabetes and nephropathy. NEngl J Med 2004;351:1952-61.
40. Redón J, Luque-Otero M, Martell N, Chaves FJ; POLPRI Investigators. Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Phamacogenomics J 2005;5:14-20.
41. Ruilope LM, Redon J, Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme. Vasc Health Risk Manag 2007;3:1-9.
42. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996;94:1682-9.